PDS Biotechnology (PDSB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on the stock and has a $13.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Pantginis has given his Buy rating due to a combination of factors, primarily focusing on the promising potential of PDS Biotechnology’s Versamune HPV in addressing the unmet needs in HPV16+ head and neck squamous cell carcinoma (HNSCC). The company recently hosted a Key Opinion Leader (KOL) event, featuring experts from The Institute of Cancer Research and the Mayo Clinic, who emphasized the growing prevalence of HPV16+ cases and the inadequacy of current treatments.
The encouraging data from the VERSATILE-002 study, presented at the ASCO conference, further supports the clinical potential of Versamune HPV. The combination of Versamune HPV with pembrolizumab has shown to exceed current treatment benchmarks in terms of overall survival and response rates. This positions the therapy well for success in the ongoing Phase 3 VERSATILE-003 trial, which aims to further validate its efficacy against the standard pembrolizumab monotherapy. These factors collectively underpin Pantginis’s optimistic outlook and Buy rating for PDS Biotechnology’s stock.
According to TipRanks, Pantginis is an analyst with an average return of -20.2% and a 27.80% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Cytokinetics, Kura Oncology, and Krystal Biotech.